ArticleTherapeutic advances in musculoskeletal disease2021
Large-vessel involvement is predictive of multiple relapses in giant cell arteritis.
Article in Therapeutic advances in musculoskeletal disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Pooled it
- Diagnostic Challenges and Modern Therapeutic Strategies in Giant Cell Arteritis.Diagnostics (Basel, Switzerland) · 2026Review
- Scoping review of clinical, laboratory, histopathological and imaging predictors of relapse in adults with biopsy- or temporal artery ultrasound-confirmed giant cell arteritis on standard therapy with glucocorticoids alone or in combination with biologics.Rheumatology advances in practice · 2026Review
- Longitudinal changes on cranial magnetic resonance imaging in relapsing giant cell arteritis.Seminars in arthritis and rheumatism · 2025Article
- Treatment and risk of relapse in GCA in Western Norway 2013-2020: a retrospective cohort study.Rheumatology advances in practice · 2025Article
- Comparative analysis of arterial involvement in predominant cranial and isolated extracranial phenotypes of giant cell arteritis usingArthritis research & therapy · 2024Article
- Article
- Article
- The DANIsh VASculitis cohort study: protocol for a national multicenter prospective study including incident and prevalent patients with giant cell arteritis and polymyalgia rheumatica.Frontiers in medicine · 2024Article
- Evaluation of baseline F-18 FDG positron emission tomography in the diagnosis and assessment of giant cell arteritis.Turkish journal of medical sciences · 2024Article
- Vascular ultrasound as a follow-up tool in patients with giant cell arteritis: a prospective observational cohort study.Frontiers in medicine · 2024Article
- Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?Rheumatology (Oxford, England) · 2023Article
- Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study.RMD open · 2023Article
- Vasculitis distribution and clinical characteristics in giant cell arteritis: a retrospective study using the new 2022 ACR/EULAR classification criteria.Frontiers in medicine · 2023Article
- Giant-cell arteritis related strokes: scoping review of mechanisms and rethinking treatment strategy?Frontiers in neurology · 2023Article
- Semi-Quantitative [International journal of molecular sciences · 2022Article
- Treatment of Giant Cell Arteritis (GCA).Journal of clinical medicine · 2022Review
- An Updated Review of Cardiovascular Events in Giant Cell Arteritis.Journal of clinical medicine · 2022Review
- Current developments in the diagnosis and treatment of giant cell arteritis.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiant cell arteritis (GCA) is the most common systemic vasculitis. Relapses are frequent. The aim of this study was to identify relapse risk factors in patients with GCA with complete large-vessel imaging at diagnosis.
methodsPatients with GCA followed in our institution between April 1998 and April 2018 were included retrospectively. We included only patients who had undergone large vascular imaging investigations at diagnosis by computed tomography (CT)-scan and/or positron emission tomography (PET)-scan and/or angio-magnetic resonance imaging (MRI). Clinical, biological, and radiological data were collected. Relapse was defined as the reappearance of GCA symptoms, with concomitant increase in inflammatory markers, requiring treatment adjustment. Relapsing patients (R) and non-relapsing patients (NR) were compared. Relapse and multiple relapses (>2) risk factors were identified in multivariable Cox analyses.
resultsThis study included 254 patients (73.2% women), with a median age of 72 years at diagnosis and a median follow up of 32.5 months. At diagnosis, 160 patients (63%) had an inflammatory large-vessel involvement on imaging, 46.1% (117 patients) relapsed at least once, and 21.3% (54 patients) had multiple relapses. The median delay of first relapse after diagnosis was 9 months. The second relapse delay was 21.5 months. NR patients had more stroke at diagnosis than R (
conclusionMale gender was a protective factor for GCA relapse and peripheral musculoskeletal manifestations appeared as a relapsing risk factor. Moreover, this study identified a particular clinical phenotype of multi-relapsing patients with GCA, characterized by peripheral musculoskeletal manifestations, negative temporal artery biopsy, and large-vessel involvement with upper limb ischemia or inflammation of arm arteries. PLAIN LANGUAGE SUMMARY:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.